Grounded in a culture of collaboration, connectivity and data-based science, MD Anderson's research yields transformative findings that are shifting patient care and improving patients’ lives across the globe. From pioneering cellular therapies to the latest bispecific antibodies and targeted therapies, our work is leading to more personalized diagnoses, treatments and improved outcomes for patients.
At the 2024 ASH Annual Meeting and Exposition, our experts showcase their latest research with colleagues from across the globe for large-scale discussion.
Keep up with presentation highlights from our experts as well as learn more about our pioneering research across the field of hematology below.
Featured articles
MD Anderson Research Highlights: ASH 2024...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
This special edition features upcoming oral presentations by MD Anderson researchers at the 66th American...
ASH: Monoclonal antibody therapy improves...
ABSTRACT: 805
SAN DIEGO – Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.
Data from the Phase Ib trial were...
ASH: Triplet combination regimens...
ABSTRACTS: 216, 219, 1011
SAN DIEGO ― Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content...
Meet the Experts
Stop by booth 1949 to ask a question, learn about training and career opportunities and continue the conversation on key presentations with our experts. Check back for more updates to the Meet the Experts schedule soon.
Saturday, December 7
11–11:30 a.m. PT
Training at MD Anderson (Part 1)
Krina Patel, M.D.
Associate Program Director, Hematology/Oncology Fellowship – Malignant Hematology
11:15–11:45 a.m. PT
Cell therapy: What's on the horizon (Part 1)
Sattva Neelapu, M.D.
Professor, Lymphoma and Myeloma
12–12:30 p.m. PT
New approaches to treating aggressive lymphomas
Sairah Ahmed, M.D.
Associate Professor, Lymphoma and Myeloma
12–1 p.m. PT
MD Anderson Cancer Network®: Partnering to Eliminate Cancer
Carter Davis, M.D.
Ochsner MD Anderson Cancer Center
Naveen Pemmaraju, M.D.
Director, Leukemia for Cancer Network
Matthew Ulrickson, M.D.
Chief, Section of Hematology
Banner MD Anderson Cancer Center
12:30–1 p.m. PT
Advances in stem cell transplants
Gheath Al-Atrash, D.O., Ph.D.
Associate Professor, Hematopoietic Biology and Malignancy
Uday Popat, M.D.
Professor, Stem Cell Transplantation
2–2:30 p.m. PT
Training at MD Anderson (Part 2)
Qaiser Bashir, M.D.
Program Director, Stem Cell Transplantation and Cellular Therapy Fellowship
Guillermo Garcia-Manero, M.D.
Training Program Director, Leukemia Fellowship Program
Tapan Kadia, M.D.
Associate Training Program Director, Leukemia Fellowship Program
Sanam Loghavi, M.D.
Hematopathology Fellowship
3–3:30 p.m. PT
Cell therapy: What's on the horizon (Part 2)
Elizabeth Shpall, M.D.
Professor, Stem Cell Transplantation and Cellular Therapy
3:30–4 p.m. PT
Targeted BCMA in multiple myeloma
Hans Lee, M.D.
Associate Professor, Lymphoma and Myeloma
Robert Orlowski, M.D., Ph.D.
Professor, Lymphoma and Myeloma
Oren Pasvolsky, M.D.
Assistant Professor, Lymphoma and Myeloma
Sunday, December 8
Monday, December 9
Why Houston?
As America's fourth largest city, Houston has a lot to offer. Find out why Houston is a hub for scientific and medical excellence.
Get to know our oncologists
Some of our experts who will be presenting at ASH 2024
Leukemia
Alexandre Bazinet, M.D.C.M.
Lymphoma
Christopher Flowers, M.D.
Leukemia
Nitin Jain, M.D.
Multiple myeloma
Krina Patel, M.D.
Leukemia
Jayastu Senapati, M.B.B.S., M.D., D.M.
Lymphoma
Jason Westin, M.D.
Institutes at MD Anderson
James P. Allison Institute
Institute for Cell Therapy Discovery & Innovation
Institute for Data Science in Oncology
Education and Training at MD Anderson
MD Anderson academic programs are competitive and comprehensive. We offer educational opportunities from undergraduate degrees to graduate medical education opportunities.
Breakthroughs in cancer treatment